Jan. 2, 2012–IBI analyst Natalie Gottlieb: Increase exposure to Teva.In response to the resignation of Teva CEO Shlomo Yanai, Israeli analysts believe that its effect on Teva’s shares will be positive. “We expect that the resignation announcement will have a positive effect on Teva’s share price,” writes IBI analyst Natalie Gottlieb. The last time that a CEO resigned from Teva (Israel Makov, five years ago) Teva’s share price fell 4% that same day, but quickly corrected. Shlomo Yanai will resign in May, and Dr. Jeremy Levin, a senior executive from Bristol-Myers Squibb, will take his place. Teva will hold a press conference at 11:30 am today, which “Globes” will broadcast live.(Globes)
You must be Logged in to post comment.
